成品药

Search documents
京新药业:10月10日召开董事会会议
Mei Ri Jing Ji Xin Wen· 2025-10-10 13:14
每经AI快讯,京新药业(SZ 002020,收盘价:19.64元)10月10日晚间发布公告称,公司第九届第一次 董事会会议于2025年10月10日在公司行政楼一楼会议室召开。会议审议了《关于选举第九届董事会各专 业委员会委员的议案》等文件。 每经头条(nbdtoutiao)——天水麻辣烫、淄博烧烤、荣昌卤鹅⋯⋯"泼天流量"退去后,这些城市怎么 样了? (记者 王晓波) 截至发稿,京新药业市值为169亿元。 2025年1至6月份,京新药业的营业收入构成为:成品药占比58.28%,原料药占比22.44%,医用器械占 比17.32%,其他业务占比1.95%。 ...
京新药业:累计回购约4727.13万股
Mei Ri Jing Ji Xin Wen· 2025-10-09 10:47
每经AI快讯,京新药业(SZ 002020,收盘价:20.28元)10月9日晚间发布公告称,截至2025年9月30 日,公司通过股份回购专用证券账户以集中竞价方式回购公司股份约4727.13万股,占公司目前总股本 的5.49%,购买股份最高成交价为14.41元/股,购买股份最低成交价为11.86元/股,成交总金额约为6.09 亿元。 截至发稿,京新药业市值为175亿元。 每经头条(nbdtoutiao)——与美元脱钩后,暴涨102倍,揭秘黄金疯涨背后神秘的"无形之手"!专家: 推动金价上涨的逻辑没有变 2025年1至6月份,京新药业的营业收入构成为:成品药占比58.28%,原料药占比22.44%,医用器械占 比17.32%,其他业务占比1.95%。 (记者 曾健辉) ...
京新药业:9月29日召开董事会会议
Mei Ri Jing Ji Xin Wen· 2025-09-29 12:25
每经头条(nbdtoutiao)——重磅解读!中国将不寻求WTO新的特殊和差别待遇,意味着什么? (记者 曾健辉) 每经AI快讯,京新药业(SZ 002020,收盘价:19.66元)9月29日晚间发布公告称,公司第八届第十八 次董事会会议于2025年9月29日以电话及传真方式召开。会议审议了《关于提请股东会授权董事会办理 第四期员工持股计划相关事宜的议案》等文件。 2025年1至6月份,京新药业的营业收入构成为:成品药占比58.28%,原料药占比22.44%,医用器械占 比17.32%,其他业务占比1.95%。 截至发稿,京新药业市值为169亿元。 ...
Many pharma companies already made U.S. investment promises, says Citi's Geoff Meacham
Youtube· 2025-09-26 20:50
Core Viewpoint - President Trump announced a 100% tariff on pharmaceutical products entering the US starting October 1st unless companies establish manufacturing plants in the US, with the EU and Japan exempt from this tariff [1] Group 1: Market Reaction - The pharmaceutical sector is responding positively to the news, with stocks of major pharmaceutical companies trading higher [2] - This tariff announcement is perceived as a "d-risking event" for the pharmaceutical industry, alleviating investor uncertainty since the initial tariff announcement on April 2nd [3] Group 2: Manufacturing Plans - Many pharmaceutical companies have already announced plans to increase manufacturing in the US, which may mitigate the impact of the tariffs [4] - A comprehensive list of companies that have made public commitments to expand manufacturing includes major players in both the US and Europe, indicating a proactive approach to the new tariff environment [5] Group 3: Future Investments - Companies in the pharmaceutical sector typically have long-term plans (5 to 10 years) for capital expenditures and manufacturing growth, which may have been accelerated due to the tariff announcement [7] - There is an expectation that new manufacturing plants will begin construction soon, reflecting a genuine commitment to increasing domestic production [8]
京新药业:9月24日召开董事会会议
Mei Ri Jing Ji Xin Wen· 2025-09-24 11:40
Group 1 - The company, Jingxin Pharmaceutical, announced the convening of its 17th board meeting on September 24, 2025, to review governance system proposals [1] - For the first half of 2025, Jingxin Pharmaceutical's revenue composition was as follows: finished drugs accounted for 58.28%, raw materials for 22.44%, medical devices for 17.32%, and other businesses for 1.95% [1] - As of the report date, Jingxin Pharmaceutical's market capitalization was 18.6 billion yuan [1]
华海药业:约4115.23万股限售股9月25日解禁
Sou Hu Cai Jing· 2025-09-19 08:36
Group 1 - Company Huahai Pharmaceutical announced that approximately 41.15 million restricted shares will be unlocked and listed for trading on September 25, 2025, accounting for about 2.75% of the company's total share capital [1] - For the year 2024, the revenue composition of Huahai Pharmaceutical is as follows: finished drug sales account for 60.32%, raw materials and intermediates sales account for 38.19%, technical services account for 0.66%, other businesses account for 0.55%, and other industries account for 0.28% [1] - The current market capitalization of Huahai Pharmaceutical is 34.4 billion yuan [2]
尔康制药(300267.SZ):暂无“肝纤维化药物”相关研发项目
Ge Long Hui· 2025-09-12 07:26
Group 1 - The company, Erkang Pharmaceutical (300267.SZ), stated that its main business includes the production and sales of excipients, raw materials, finished drugs, and new energy materials [1] - The company currently has no research and development projects related to "liver fibrosis drugs" [1]
美诺华股价涨5.84%,万家基金旗下1只基金重仓,持有20.18万股浮盈赚取30.67万元
Xin Lang Cai Jing· 2025-09-01 05:21
Group 1 - Menova's stock price increased by 5.84% to 27.56 CNY per share, with a trading volume of 439 million CNY and a turnover rate of 7.71%, resulting in a total market capitalization of 6.058 billion CNY [1] - Menova's main business includes the research, production, and sales of specialty raw materials (including intermediates) and finished drugs, with revenue composition as follows: intermediates and raw materials 57.74%, formulations 29.53%, CDMO 8.87%, trade 3.52%, and others 0.34% [1] Group 2 - Wan Jia Fund has one fund heavily invested in Menova, specifically the Wan Jia Guo Zheng 2000 ETF, which held 201,800 shares in the second quarter, accounting for 0.49% of the fund's net value, making it the second-largest holding [2] - The Wan Jia Guo Zheng 2000 ETF has a total size of 808 million CNY and has achieved a year-to-date return of 29.99%, ranking 1313 out of 4223 in its category, with a one-year return of 76.26%, ranking 872 out of 3780 [2]
京新药业(002020.SZ):上半年净利润3.88亿元 同比下降3.54%
Ge Long Hui A P P· 2025-08-26 12:43
Core Viewpoint - Jingxin Pharmaceutical (002020.SZ) reported a decline in revenue and net profit for the first half of the year, indicating challenges in the pharmaceutical sector while showing growth in medical device revenue [1] Financial Performance - The company achieved a total revenue of 2.017 billion yuan, a year-on-year decrease of 6.20% [1] - Finished drug revenue was 1.175 billion yuan, down 9.68% year-on-year [1] - Raw material drug revenue reached 453 million yuan, a decline of 9.59% year-on-year [1] - Medical device revenue increased to 349 million yuan, reflecting a growth of 12.01% year-on-year [1] - The net profit attributable to the parent company was 388 million yuan, a decrease of 3.54% year-on-year [1] - The net profit after deducting non-recurring gains and losses was 360 million yuan, showing a year-on-year increase of 7.78% [1]
华海药业:为子公司华海建诚提供不超过2.05亿元担保
Mei Ri Jing Ji Xin Wen· 2025-08-25 12:04
Group 1 - Company announced a credit guarantee of up to 205 million yuan for its wholly-owned subsidiary Huahai Jiancheng to meet funding needs [1] - As of the announcement date, the total external guarantees provided by the company and its subsidiaries amount to approximately 3.572 billion yuan, which is 40.15% of the latest audited equity attributable to shareholders [1] - The breakdown of guarantees includes approximately 3.105 billion yuan for subsidiaries (34.89% of the latest audited equity) and 263 million yuan for associated companies (2.95% of the latest audited equity) [1] Group 2 - For the year 2024, the revenue composition of Huahai Pharmaceutical is as follows: finished drug sales account for 60.32%, raw materials and intermediates sales account for 38.19%, technical services account for 0.66%, other businesses account for 0.55%, and other industries account for 0.28% [1] - The current market capitalization of Huahai Pharmaceutical is 34 billion yuan [2]